ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 131 filers reported holding ARRAY BIOPHARMA INC in Q2 2016. The put-call ratio across all filers is 2.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $26,600,000 | +98418.5% | 574,144 | +29694.7% | 1.31% | +65350.0% |
Q4 2018 | $27,000 | -75.5% | 1,927 | -73.3% | 0.00% | -66.7% |
Q3 2018 | $110,000 | +86.4% | 7,208 | +105.1% | 0.01% | +50.0% |
Q2 2018 | $59,000 | -92.2% | 3,515 | -92.4% | 0.00% | -92.7% |
Q1 2018 | $755,000 | +57.3% | 46,252 | +23.4% | 0.06% | +41.0% |
Q4 2017 | $480,000 | +879.6% | 37,494 | +842.8% | 0.04% | +875.0% |
Q3 2017 | $49,000 | +81.5% | 3,977 | +21.4% | 0.00% | +33.3% |
Q2 2017 | $27,000 | -70.0% | 3,276 | -87.0% | 0.00% | -76.9% |
Q2 2016 | $90,000 | +136.8% | 25,200 | +93.8% | 0.01% | +160.0% |
Q1 2016 | $38,000 | -24.0% | 13,000 | +10.2% | 0.01% | -37.5% |
Q4 2015 | $50,000 | +316.7% | 11,800 | +637.5% | 0.01% | +300.0% |
Q2 2015 | $12,000 | -62.5% | 1,600 | -63.6% | 0.00% | -50.0% |
Q1 2015 | $32,000 | -76.8% | 4,400 | -85.4% | 0.00% | -77.8% |
Q2 2014 | $138,000 | +187.5% | 30,200 | +193.2% | 0.02% | +200.0% |
Q1 2014 | $48,000 | – | 10,300 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Redmile Group, LLC | 16,618,776 | $146,079,000 | 12.59% |
BVF INC/IL | 4,986,186 | $43,829,000 | 8.81% |
First Light Asset Management, LLC | 1,000,361 | $8,793,000 | 3.86% |
Crosspoint Capital Strategies, LLC | 463,005 | $4,070,000 | 3.62% |
Consonance Capital Management LP | 2,723,471 | $23,912,000 | 2.63% |
KOPP INVESTMENT ADVISORS LLC | 219,926 | $1,933,000 | 2.04% |
SPHERA FUNDS MANAGEMENT LTD. | 900,000 | $7,911,000 | 2.00% |
Orbimed Advisors | 16,088,800 | $141,421,000 | 1.80% |
Cormorant Asset Management, LP | 1,150,000 | $10,109,000 | 1.36% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,073,680 | $18,227,000 | 1.26% |